These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 8633251)

  • 1. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
    Pommier Y
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to camptothecins.
    Saleem A; Edwards TK; Rasheed Z; Rubin EH
    Ann N Y Acad Sci; 2000; 922():46-55. PubMed ID: 11193924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
    Pommier Y; Pourquier P; Fan Y; Strumberg D
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):83-105. PubMed ID: 9748515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular resistance to camptothecins.
    Pommier Y; Gupta M; Valenti M; Nieves-Neira W
    Ann N Y Acad Sci; 1996 Dec; 803():60-73. PubMed ID: 8993501
    [No Abstract]   [Full Text] [Related]  

  • 6. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
    Tsunoda T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
    [No Abstract]   [Full Text] [Related]  

  • 8. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
    Murren JR; Beidler DR; Cheng YC
    Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
    [No Abstract]   [Full Text] [Related]  

  • 9. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
    Morris EJ; Geller HM
    J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology of camptothecin and its derivatives].
    Rivory LP; Robert J
    Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage.
    Sun M; Duann P; Lin CT; Zhang H; Liu LF
    Ann N Y Acad Sci; 2000; 922():340-2. PubMed ID: 11193917
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
    Perego P; Cossa G; Tinelli S; Corna E; Carenini N; Gatti L; De Cesare M; Ciusani E; Zunino F; Luison E; Canevari S; Zaffaroni N; Beretta GL
    Biochem Pharmacol; 2012 Jan; 83(1):27-36. PubMed ID: 21978643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis.
    Li XG; Haluska P; Hsiang YH; Bharti AK; Kufe DW; Liu LF; Rubin EH
    Biochem Pharmacol; 1997 Apr; 53(7):1019-27. PubMed ID: 9174116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.
    Hautefaye P; Cimetière B; Pierré A; Léonce S; Hickman J; Laine W; Bailly C; Lavielle G
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2731-5. PubMed ID: 12873503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
    Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
    J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.
    Rivory LP; Robert J
    Pharmacol Ther; 1995; 68(2):269-96. PubMed ID: 8719971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.